CA2977612A1 - Nanoparticulate composition - Google Patents

Nanoparticulate composition Download PDF

Info

Publication number
CA2977612A1
CA2977612A1 CA2977612A CA2977612A CA2977612A1 CA 2977612 A1 CA2977612 A1 CA 2977612A1 CA 2977612 A CA2977612 A CA 2977612A CA 2977612 A CA2977612 A CA 2977612A CA 2977612 A1 CA2977612 A1 CA 2977612A1
Authority
CA
Canada
Prior art keywords
composition
oil
particles
minocycline
nanoparticulate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2977612A
Other languages
English (en)
French (fr)
Inventor
Madhusudhan BOMMAGANI
Subhas Balaram Bhowmick
Prashant Kane
Vaibhav Dubey
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sun Pharma Advanced Research Co Ltd
Original Assignee
Sun Pharma Advanced Research Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sun Pharma Advanced Research Co Ltd filed Critical Sun Pharma Advanced Research Co Ltd
Publication of CA2977612A1 publication Critical patent/CA2977612A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/65Tetracyclines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0014Skin, i.e. galenical aspects of topical compositions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/06Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/12Aerosols; Foams
    • A61K9/122Foams; Dry foams
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/02Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Dispersion Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CA2977612A 2015-02-25 2016-02-25 Nanoparticulate composition Abandoned CA2977612A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IN623MU2015 2015-02-25
IN623/MUM/2015 2015-02-25
PCT/IN2016/050068 WO2016135754A1 (en) 2015-02-25 2016-02-25 Nanoparticulate composition

Publications (1)

Publication Number Publication Date
CA2977612A1 true CA2977612A1 (en) 2016-09-01

Family

ID=56789380

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2977612A Abandoned CA2977612A1 (en) 2015-02-25 2016-02-25 Nanoparticulate composition

Country Status (6)

Country Link
US (1) US10512608B2 (enExample)
EP (1) EP3261619A4 (enExample)
JP (1) JP2018506554A (enExample)
AU (1) AU2016224863A1 (enExample)
CA (1) CA2977612A1 (enExample)
WO (1) WO2016135754A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL152486A0 (en) 2002-10-25 2003-05-29 Meir Eini Alcohol-free cosmetic and pharmaceutical foam carrier
US8636982B2 (en) 2007-08-07 2014-01-28 Foamix Ltd. Wax foamable vehicle and pharmaceutical compositions thereof
WO2011013009A2 (en) 2009-07-29 2011-02-03 Foamix Ltd. Non surfactant hydro-alcoholic foamable compositions, breakable foams and their uses
EP2482788B1 (en) 2009-10-02 2022-12-14 Journey Medical Corporation Topical tetracycline compositions
US10398641B2 (en) 2016-09-08 2019-09-03 Foamix Pharmaceuticals Ltd. Compositions and methods for treating rosacea and acne
MX2023005759A (es) * 2020-11-17 2023-05-29 Arcutis Biotherapeutics Inc Composiciones y metodos para suministro de farmaco dermico profundo.

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5122519A (en) 1989-06-27 1992-06-16 American Cyanamid Company Stable, cosmetically acceptable topical gel formulation and method of treatment for acne
US8236352B2 (en) * 1998-10-01 2012-08-07 Alkermes Pharma Ireland Limited Glipizide compositions
US20040115134A1 (en) 1999-06-22 2004-06-17 Elan Pharma International Ltd. Novel nifedipine compositions
AU2002239504A1 (en) * 2000-12-06 2002-06-18 Pharmacia Corporation Laboratory scale milling process
US20080220075A1 (en) * 2002-03-20 2008-09-11 Elan Pharma International Ltd. Nanoparticulate compositions of angiogenesis inhibitors
JP4776229B2 (ja) * 2002-07-16 2011-09-21 エラン ファーマ インターナショナル,リミティド 安定なナノ粒子活性物質の液体投与組成物
US20160158261A1 (en) 2002-10-25 2016-06-09 Foamix Pharmaceuticals Ltd. Antibiotic Kit and Composition and Uses Thereof
US20070292461A1 (en) * 2003-08-04 2007-12-20 Foamix Ltd. Oleaginous pharmaceutical and cosmetic foam
GB0403702D0 (en) 2004-02-19 2004-03-24 Boots Co Plc Skincare compositions
US8920821B2 (en) * 2006-04-14 2014-12-30 Perrigo Israel Pharmaceuticals Ltd. Pharmaceutical compositions comprising silica microspheres
US20080188445A1 (en) 2007-02-02 2008-08-07 Warner Chilcott Company Inc. Tetracycline compositions for topical administration
WO2008097851A1 (en) 2007-02-02 2008-08-14 Warner Chilcott Company, Inc. Tetracycline compositions for topical administration
WO2010041141A2 (en) 2008-10-07 2010-04-15 Foamix Ltd. Oil-based foamable carriers and formulations
WO2009090495A2 (en) 2007-12-07 2009-07-23 Foamix Ltd. Oil and liquid silicone foamable carriers and formulations
WO2009158687A1 (en) 2008-06-26 2009-12-30 Anterios, Inc. Dermal delivery
US8784852B2 (en) 2009-02-27 2014-07-22 Audrey Kunin Topical skin care composition
US20120087872A1 (en) 2009-04-28 2012-04-12 Foamix Ltd. Foamable Vehicles and Pharmaceutical Compositions Comprising Aprotic Polar Solvents and Uses Thereof
EP2482788B1 (en) 2009-10-02 2022-12-14 Journey Medical Corporation Topical tetracycline compositions
US9849142B2 (en) 2009-10-02 2017-12-26 Foamix Pharmaceuticals Ltd. Methods for accelerated return of skin integrity and for the treatment of impetigo
US20140086975A1 (en) 2010-10-15 2014-03-27 Rutgers, The State University Of New Jersey Hydrogel formulation for dermal and ocular delivery
MX354137B (es) 2011-01-19 2018-02-14 Laboratory Skin Care Inc Composiciones topicas de minociclina y metodos de uso de la misma.
PT106679B (pt) 2012-11-27 2015-03-25 Hovione Farmaciencia Sa Formulações tópicas de tetraciclinas, sua preparação e usos
WO2015075640A1 (en) 2013-11-20 2015-05-28 Lupin Limited Stable pharmaceutical formulation(s) of tetracycline antibiotic
MY188541A (en) 2014-01-29 2021-12-21 Vyome Therapeutics Ltd Besifloxacin for the treatment of resistant acne

Also Published As

Publication number Publication date
WO2016135754A1 (en) 2016-09-01
US20180036243A1 (en) 2018-02-08
EP3261619A4 (en) 2018-10-24
JP2018506554A (ja) 2018-03-08
AU2016224863A1 (en) 2017-10-12
EP3261619A1 (en) 2018-01-03
US10512608B2 (en) 2019-12-24

Similar Documents

Publication Publication Date Title
US10512608B2 (en) Nanoparticulate composition
KR102658256B1 (ko) 탁산 나노입자를 사용한 피부 악성 종양의 치료용 국소 요법
CN105934239A (zh) 优选包含亲脂性活性剂的脂质微胶囊和包含它的组合物,它们的制备方法和它们在皮肤病学和化妆品中的用途
US20190307656A1 (en) Foam containing unique oil globules
ES2692820T3 (es) Producto cosmético de filtro solar
CA2575906A1 (en) Compositions forming non-lamellar dispersions
JP6460988B2 (ja) 使用時泡状を呈する外用組成物
Zafar et al. Nanosuspension enhances dissolution rate and oral bioavailability of Terminalia arjuna bark extract in vivo and in vitro
EP3768241B1 (en) Topical composition comprising calcipotriol and betamethasone dipropionate
AU2024243121A1 (en) Pressurized nanoemulsion
JP4920425B2 (ja) Dopeおよびp80の非ラメラ組成物
WO2024208434A1 (en) Pressurized nanoemulsion
JP2025027473A (ja) 冷感剤組成物
EP3261618A1 (en) Method of preparing nanoparticulate topical composition
CN112004518A (zh) 气凝胶及其在化妆品应用中的用途
JP2019069912A (ja) 非水系皮膚外用組成物およびその製造方法
JP2023548965A (ja) 固相の物質及びこれを含む分散組成物
KR102048710B1 (ko) 생분해가 가능한 프럭토스 1,6-비스포스페이트 안정화 캡슐, 이의 제조 방법 및 이를 포함하는 화장료 조성물
KR20250170060A (ko) 가압 나노에멀젼
JP2025118872A (ja) 固相のシクロスポリンa及びこれを含む分散組成物
KR20240077776A (ko) 음이온 계면활성제를 사용하여 안정화된 마껍질추출물을 함유하는 화장료 조성물 및 이의 제조방법

Legal Events

Date Code Title Description
FZDE Discontinued

Effective date: 20210831

FZDE Discontinued

Effective date: 20210831